Piramal Pharma Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Piramal Pharma Limited Pharmaceutical Export Portfolio Dataset — 8 Products, $64.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Piramal Pharma Limited — Pharmaceutical Exporter Profile (2026) | 8 Products, $64.5M Trade | TransData Nexus

Piramal Pharma Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $64.5M Total Trade · DGFT Verified

Piramal Pharma Limited is an Indian pharmaceutical exporter with a total trade value of $64.5M across 8 products in 5 therapeutic categories. Based on 1,328 verified export shipments from Indian Customs (DGFT) records, Piramal Pharma Limited is the #1 Indian exporter in 1 product including Ezetimibe. Top exports include Atorvastatin ($21.4M), Calcium ($14.4M), Ezetimibe ($13.4M).

Piramal Pharma Limited — Export Portfolio & Destination Treemap

Piramal Pharma Limited pharmaceutical export portfolio — 8 products across 5 therapeutic categories. Source: Indian Customs (DGFT).

Who is Piramal Pharma Limited? — Company Overview & Market Position

Piramal Pharma Limited (PPL) was established on March 4, 2020, as a demerged entity from Piramal Enterprises, marking its emergence as a standalone pharmaceutical company. Headquartered in Mumbai, Maharashtra, PPL operates as a public limited company with the Corporate Identification Number (CIN) U24297MH2020PLC338592. The company is a subsidiary of the Piramal Group, a diversified conglomerate with interests spanning pharmaceuticals, financial services, and real estate. The Piramal Group has a global presence, operating in over 30 countries and more than 100 markets, with a workforce of over 10,000 employees from 21 diverse nationalities.

In the fiscal year 2024, PPL reported a revenue of ₹8,605 crore, with a net operating income of ₹8,171 crore. The company's assets stood at ₹12,822 crore, and it achieved a profit of ₹18 crore, resulting in a net worth of ₹7,911 crore. As of March 2026, PPL employs approximately 5,476 individuals, reflecting its significant role in the pharmaceutical industry. The company's official website is www.piramalpharma.com.

What Does Piramal Pharma Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Atorvastatin$21.4M

Product Portfolio — Top 8 by Export Value

Piramal Pharma Limited exports 8 pharmaceutical products across 5 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Atorvastatin	Cardiovascular	$21.4M	429	2.0%	2
2	Calcium	Vitamins & Supplements	$14.4M	289	1.6%	3
3	Ezetimibe	Lipid & Metabolism	$13.4M	269	2.6%	1
4	Carvedilol	Cardiovascular	$7.0M	141	7.2%	3
5	Iron	Vitamins & Supplements	$3.8M	105	0.8%	15
6	Spironolactone	Diuretics	$2.2M	44	1.1%	7
7	Diltiazem	Cardiovascular	$1.9M	37	10.3%	3
8	Trimethoprim	Advanced Antibiotics	$344.3K	14	1.3%	14

Piramal Pharma Limited exports 8 pharmaceutical products across 5 therapeutic categories with a total export value of $64.5M. The company is the #1 Indian exporter in 1 product: Ezetimibe. The top category is Cardiovascular (47.0% of portfolio), followed by Vitamins & Supplements (28.2%), indicating a concentrated portfolio with the top 5 products accounting for 93.2% of total export value.

Piramal Pharma Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Piramal Pharma Limited operates 17 global development and manufacturing facilities, strategically located across North America, Europe, and Asia. These facilities are designed to support the entire drug lifecycle, offering services from drug discovery to commercial manufacturing of both active pharmaceutical ingredients (APIs) and finished dosage forms. The company's manufacturing capabilities include the production of highly potent APIs, antibody-drug conjugates, sterile fill/finish services, peptide products, and potent solid oral drug products. This extensive network enables PPL to meet the diverse needs of its global clientele, ensuring high-quality standards and compliance with international regulatory requirements.

3Key Leadership

Piramal Pharma Limited is led by a team of seasoned professionals committed to driving the company's strategic vision and operational excellence. Peter DeYoung serves as the Chief Executive Officer (CEO) and Executive Director of Piramal Global Pharma, bringing extensive experience in the pharmaceutical industry. Nandini Piramal holds the position of Chairperson, overseeing strategy and business growth, and also heads Human Resources, Finance, Risk, IT, and Quality at Piramal Pharma. Vivek Valsaraj serves as the Chief Financial Officer (CFO) and Executive Director, contributing to the company's financial stewardship. Other key executives include Sai Ramana Ponugoti, CEO of Piramal Consumer Healthcare, and Rashida Najmi, Chief Quality Officer, who ensures the company's adherence to global quality standards.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Piramal Pharma Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Piramal Pharma Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals for its products in these regions, facilitating market access and distribution. PPL's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), and the company has filed Abbreviated New Drug Applications (ANDAs) for various products. Additionally, PPL has filed Drug Master Files (DMFs) with the FDA, ensuring compliance with U.S. regulatory standards. The company's facilities have undergone FDA inspections, maintaining a strong track record of compliance. In the European Union, PPL's manufacturing sites hold EU Good Manufacturing Practice (GMP) certificates, and the company has obtained marketing authorizations for its products. PPL's products are also approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, the Therapeutic Goods Administration (TGA) in Australia, and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, demonstrating the company's commitment to meeting the stringent regulatory requirements of these markets.

2Emerging Markets

Piramal Pharma Limited has strategically expanded its footprint in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's products are prequalified by the World Health Organization (WHO), enabling access to these markets and facilitating the supply of essential medicines. PPL's WHO prequalification ensures that its products meet international quality standards, which is crucial for market entry and acceptance in these regions. The company's global distribution network, spanning over 100 countries, supports its efforts to address the healthcare needs of diverse populations, particularly in emerging markets where access to quality pharmaceuticals is vital.

Piramal Pharma Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Piramal Pharma Limited has a robust engagement with the U.S. Food and Drug Administration (FDA), underscoring its commitment to the U.S. market. The company's manufacturing facilities are registered with the FDA, and PPL has filed multiple Abbreviated New Drug Applications (ANDAs) for various products, seeking approval for the marketing of generic drugs in the U.S. Additionally, PPL has submitted Drug Master Files (DMFs) to the FDA, providing detailed information about the manufacturing processes and quality controls of its products. The company's facilities have undergone FDA inspections, maintaining a strong track record of compliance with U.S. regulatory standards. This engagement reflects PPL's dedication to ensuring the safety, efficacy, and quality of its products for the U.S. market.

2WHO & EU GMP

Piramal Pharma Limited's commitment to quality is demonstrated through its adherence to international standards, including WHO prequalification and EU Good Manufacturing Practice (GMP) certifications. The company's products are prequalified by the World Health Organization (WHO), ensuring they meet international quality standards and are eligible for procurement by international organizations and governments. In the European Union, PPL's manufacturing sites hold EU GMP certificates, indicating compliance with the stringent manufacturing standards required for marketing pharmaceutical products in the EU. These certifications reflect PPL's dedication to maintaining high-quality manufacturing processes and its ability to meet the regulatory requirements of key international markets.

Piramal Pharma Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Piramal Pharma Limited operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products and services. In the Contract Development and Manufacturing Organization (CDMO) segment, PPL competes with companies such as Lonza Group, WuXi AppTec, and Catalent, which also provide end-to-end development and manufacturing solutions across the drug lifecycle. In the hospital generics market, PPL faces competition from firms like Fresenius Kabi, Baxter International, and Hikma Pharmaceuticals, which offer a range of injectable and inhalation anesthetic products. In the consumer healthcare segment, PPL competes with companies like Procter & Gamble, Johnson & Johnson, and GlaxoSmithKline, which have established brands in the over-the-counter market. PPL's market share varies across different therapeutic categories, with its top five products accounting for 93.2% of its total export value. This concentration indicates a strong focus on specific product lines, which can

TransData Nexus Research · DGFT export records, industry analysisMar 2026

Frequently Asked Questions — Piramal Pharma Limited

How many pharmaceutical products does Piramal Pharma Limited export from India?

Piramal Pharma Limited exports 8 pharmaceutical products across 5 therapeutic categories. The top exports are Atorvastatin ($21.4M), Calcium ($14.4M), Ezetimibe ($13.4M), Carvedilol ($7.0M), Iron ($3.8M). Total export value is $64.5M.

What is Piramal Pharma Limited's total pharmaceutical export value?

Piramal Pharma Limited's total pharmaceutical export value is $64.5M, based on 1,328 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Piramal Pharma Limited the #1 Indian exporter?

Piramal Pharma Limited is the #1 Indian exporter in 1 products: Ezetimibe (2.6% market share).

What therapeutic categories does Piramal Pharma Limited cover?

Piramal Pharma Limited exports across 5 therapeutic categories. The largest are Cardiovascular (47.0%, 3 products), Vitamins & Supplements (28.2%, 2 products), Lipid & Metabolism (20.8%, 1 products).

Get Full Piramal Pharma Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.